Skip to main content

The Factor VIII Inhibitor Assays can be Standardized: Results of a Workshop.

Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P

Publication: J Thromb Haemost (2011) • Vol 9 • Page 2003-2008PMID: 21854536View on PubMed

Purpose

The purpose of this paper was to find the source of high interlaboratory variability in the measurement of factor VIII inhibitor activity.

Conclusion

The use of buffered plasma as a reference and undiluted specimens or specimens diluted with factor VIII deficient plasma led to lower inhibitor activities than when the substrate was unbuffered or the specimen was diluted with buffer. Adoption of a standard protocol involving the use of the Nijmegan assay and universal reagents and dilutions resulted in the interlaboratory coefficient of variance (CV) of the inhibitor activities dropping to 8.4 compared to a CV of 46.8 when all laboratories used their own reagents and protocols.

Studies (1)

Purpose

The purpose of this study was to determine the effect of substrate, diluent and dilution on the measurement of factor VIII inhibitor activity in plasma.

Summary of Findings

Inhibitor activity in the inhibitor negative pool was found to be higher in laboratories that used non-buffered normal pooled plasma rather than commercial plasma or buffered homemade normal pooled plasma as substrate (p<0.02). When each lab used their own reagents, the mean inhibitor activity was 0.10-0.20 BU/mL), but when all laboratories used the same buffered normal plasma substrate and factor VIII deficient plasma reference, the mean measured inhibitor activity was 0.00 BU/mL, with a range of 0.00-0.20 BU/mL. There was a strong correlation between inhibitor activity and the dilution factor (p<0.01). When specimens were diluted in buffer, the inhibitor activity was higher than when specimens were diluted with factor FVIII deficient plasma (p<0.02) or were undiluted (p<0.03). By adopting a standard protocol involving the use of the Nijmegan assay with universal reagents and dilutions, the interlaboratory CV of the inhibitor activities dropped to 8.4 compared to a CV of 46.8 when all laboratories used there own reagents and protocols.
  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Not specified
    Other diagnoses
  • Platforms

    ProteinEnzyme assay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Hemophilia
    Biospecimen Aliquots and ComponentsBiospecimen components
    Buffered normal pooled plasma
    Commercial plasma
    Non-buffered normal pooled plasma
    Biospecimen Aliquots and ComponentsBiospecimen mixing
    1:10
    1:2
    1:5
    Diluted in buffer
    Diluted with factor FVIII deficient plasma
    Undiluted